-
Mashup Score: 4Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers - 2 year(s) ago
The complex genomic landscape of RAS-mutant tumors is reflective of selection processes in a cancer lineage–specific and context-dependent manner, highlighting differential therapeutic vulnerabilities that can be clinically translated.
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis - PubMed - 2 year(s) ago
Proliferative chronic myelomonocytic leukemia (pCMML), an aggressive CMML subtype, is associated with dismal outcomes. RAS pathway mutations, mainly NRASG12D, define the pCMML phenotype as demonstrated by our exome sequencing, progenitor colony assays and a Vav-Cre-NrasG12D mou …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
Trial based on excellent preclinical data generated in our lab by @LashoTerra @Ryan_M_Carr @MoritzBinderMD https://t.co/UyUEdxLE53 #RAS mutations drive #pCMML with #KMT2A mediated regulation of #H3K4Me1
-
-
Mashup Score: 3Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers - 2 year(s) ago
The complex genomic landscape of RAS-mutant tumors is reflective of selection processes in a cancer lineage–specific and context-dependent manner, highlighting differential therapeutic vulnerabilities that can be clinically translated.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Analysis of NGS data from 66,372 tumors and 51 cancer types from @AACR Project GENIE reveals the complex genomic landscape of #RAS mutant tumors and highlights lineage-specific differential vulnerabilities. https://t.co/qZDOKZH3bf @BiagioMd @DrMarkAwad @christine_lovly @ValsamoA https://t.co/6Bm1dgiLqV
-
-
Mashup Score: 4
Original Article from The New England Journal of Medicine — Renin–Angiotensin System Inhibition in Advanced Chronic Kidney Disease
Source: New England Journal of MedicineCategories: Cardiologists, Latest HeadlinesTweet-
RAS Inhibition in Advanced CKD - STOP ACEI Trial Ditching #RAS inhibitors in advanced #CKD didn't help to slow kidney ⤵️ (95% CI - 2.5 to 1.0, P=0.42) Findings do not support discontinuation to improve kidney function https://t.co/X39zHJhyQs @NEJM #NephTwitter #CardioTwitter https://t.co/1M0tf5OedR
-
-
Mashup Score: 1Cancer drugs are closing in on some of the deadliest mutations - 2 year(s) ago
The protein KRAS, mutated in many cancers, was deemed ‘undruggable’. Now scientists are hoping to save lives with a batch of new compounds that target it.
Source: www.nature.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
Cancer drugs are closing in on some of the deadliest mutations https://t.co/GzVbDGSR2M #RAS #KRAS
-
-
Mashup Score: 0
This co-clinical trial of combined MEK-CDK4/6 inhibition in RAS mutant colorectal cancer demonstrates therapeutic efficacy in patient-derived xenografts and safety in patients, identifies biomarkers of response, and uncovers targetable mechanisms of resistance.
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Targeting #RAS Mutant #ColorectalCancer with Dual Inhibition of MEK and CDK4/6, by Sorokin et al. https://t.co/iMkJfI1BX0 @VanMorrisMD @MDAndersonNews https://t.co/uwHg7IDUDv
-
-
Mashup Score: 7Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers - 2 year(s) ago
Abstract. The RAS family of small GTPases represents the most commonly activated oncogenes in human cancers. To better understand the prevalence of somatic RAS mutations and the compendium of genes that are co-altered in RAS mutant tumors, we analyzed targeted next-generation sequence data of 607,863 mutations from 66,372 tumors in 51 cancer types in the AACR Project GENIE Registry. Bayesian…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Analysis of NGS data from 66,372 tumors and 51 cancer types from @AACR Project GENIE reveals the complex genomic landscape of #RAS mutant tumors and highlights lineage-specific differential vulnerabilities. https://t.co/1yQ7Yz0ohX @BiagioMd @DrMarkAwad @christine_lovly @ValsamoA https://t.co/2rYKlAmnIb
-
-
Mashup Score: 5The RAS Initiative - 2 year(s) ago
NCI established the RAS Initiative to explore innovative approaches for attacking the proteins encoded by mutant forms of RAS genes and to ultimately create effective, new therapies for RAS-related cancers.
Source: National Cancer InstituteCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
More than 30% of cancers are driven by mutations of the #RAS family of genes. The RAS Initiative explores innovative approaches for attacking the proteins encoded by mutant forms of RAS genes and creating effective, new therapies for RAS-related cancers. https://t.co/ivMvLbibAK https://t.co/WShlxh2sfj
-
-
Mashup Score: 1Reshaping the Preterm Heart: Shifting Cardiac Renin-Angiotensin System Towards Cardioprotection in Rats Exposed to Neonatal High-Oxygen Stress - 2 year(s) ago
Background: Approximately 10% of infants are born preterm. Preterm birth leads to short and long-term changes in cardiac shape and function. By using a rat model of neonatal high-oxygen (80%O2) expos
Source: HypertensionCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Reshaping the #Preterm #Heart: Shifting cardiac #RAS towards cardioprotection with #Ang17 in rats exposed to neonatal high-oxygen stress #Prematurity #DOHaD @mari_br_montrea @AnneMoniqueNuyt @DrAJLewandowski @pablolamata @Dartora_DR https://t.co/sqCnwc3UKi https://t.co/nw215jIA3i
-
-
Mashup Score: 4
Abstract. KRAS and NRAS mutations occur in 45% of colorectal cancers (CRC), with combined MAPK pathway and CDK4/6 inhibition identified as a potential therapeutic strategy. In the current study, this combinatorial treatment approach was evaluated in a co-clinical trial in patient-derived xenografts (PDX), and safety was established in a clinical trial of binimetinib and palbociclib in metastatic…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ICYMI: Targeting #RAS Mutant #ColorectalCancer with Dual Inhibition of MEK and CDK4/6, by Sorokin et al. https://t.co/UowZ2E1haW @skopetz @Benjohnson1112 @VanMorrisMD @MDAndersonNews https://t.co/SmozWTOO6m
-
The complex genomic landscape of #RAS-mutant tumors is described in this paper. Co-mutations with RAS are cancer lineage–specific & context-dependent manner. Enrichment in KRAS G12C mutations is seen in white females with NSCLC & colorectal carcinoma. https://t.co/D6nC35i1mD https://t.co/NwgiW1HKK4